Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
This study has been completed.
Information provided by:
First received: May 2, 2002
Last updated: June 23, 2005
Last verified: December 2003
The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.
Kidney Failure, Chronic
Renal Disease, End-Stage
Masking: Open Label
Primary Purpose: Treatment
||Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
|Ages Eligible for Study:
||21 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Basic Inclusion Criteria:
- Patients, adult men or women who are between 21 and 75 years of age who are on maintenance hemodialysis regimen for at least three (3) months prior to the study start.
- Patients who can tolerate a hemodialysis session lasting up to 9 hours.
- Patients who can tolerate a hemodialysis treatment with blood flow rates of 300 ml per minute.
- Female volunteers who are not documented to be surgically sterile must be willing to abstain from sexual intercourse during the study or be willing to use intrauterine devices or 2 forms of barrier contraception for at least 7 days prior to the initial dose of study medication and continuing through the completion of the study.
Basic Exclusion Criteria:
- Any clinically relevant abnormality identified per the investigator on the screening medical assessment or laboratory examination.
- History of regular alcohol abuse.
- Treatment with an investigational drug within 30 days.
- History of drug allergy of clinical significance in the opinion of the investigator.
- Currently taking warfarin or other anticoagulants.
- Currently taking NSAIDs (with the exception of aspirin).
- Individuals who are obese.
- Any history of bleeding disorder.
- Any subject with a screening resting systolic blood pressure >180 mmHg and/or resting diastolic blood pressure of >100 mmHg unless, in the opinion of the principal investigator, the blood pressures would not endanger the subject while participating in this trial.
- Concurrent uncontrolled cardiovascular, hematologic, respiratory, CNS, gastrointestinal disease or chronic alcoholism.
- Anemia defined as a hematocrit of < 30 and hemoglobin < 10g/dL.
- Concurrently taking (within the past 30 days) phenytoin, cimetidine, rifampin, cyclosporin or tacrolimus.
- Known hypersensitivity to Argatroban or related compounds.
- Significant hepatic insufficiency as defined by total bilirubin greater than 1.5 mg/dL or transaminase (ALT, AST) elevations greater than 2 times the upper limit of the laboratory reference range.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00035178
|University of Chicago, Section of Nephrology
|Chicago, Illinois, United States, 60637 |
|DaVita Clinical Research
|Minneapolis, Minnesota, United States, 55404 |
Texas Biotechnology Corporation
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 2, 2002
||June 23, 2005
||United States: Food and Drug Administration
Keywords provided by Encysive Pharmaceuticals:
End-stage renal disease
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 16, 2013
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Serine Proteinase Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors